On November 5, 2018 UCLB spinout Orchard Therapeutics, a biopharmaceutical company dedicated to transforming the lives of patients with serious and life-threatening rare diseases through autologous ex vivo gene therapies, reported the closing of its initial public offering of 16,103,572 American Depositary Shares ("ADSs"), each representing an ordinary share at an initial public offering price of $14.00 per share (Press release, UCLB, NOV 5, 2018, View Source [SID1234530722]). The gross proceeds from the offering were $225.5 million before deducting underwriting commissions and estimated offering expenses.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Orchard Therapeutics was founded in 2015, based on research arising from the groups of Prof. Bobby Gaspar and Prof. Adrian Thrasher, at the UCL Institute of Child Health.